Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Lasers aren’t just for directing presentations, playing tag or annoying cats. They can also serve as virus hunters.
South San Francisco-based Freenome closed on an oversubscribed $270 million Series C financing.
A new, 64-page study that has not been peer-reviewed, extrapolates the number of infections that stemmed from the company’s corporate meeting held at the Marriott Long Wharf hotel in February.
AbbVie and Harvard University entered into a $30 million collaborative research alliance to develop therapies against emergent viral infections, with a focus on those caused by coronaviruses and by viruses that lead to hemorrhagic fever.
“I have been criticized for remarks I made Sunday night about the benefits of convalescent plasma,” Hahn tweeted. “The criticism is entirely justified. What I should have said better is that the data show a relative risk reduction not an absolute risk reduction.”
ATAI Life Sciences announced on Monday that it has launched EmpathBio, a wholly-owned subsidiary focused on developing derivatives of 3,4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.
Under terms of the licensing deal, Morphic will receive an infusion of $20 million for the license fee along with potential future development milestone payments and royalties from the sales of any commercialized candidates.
A novel, surface enhanced Raman spectroscopy (SERS) assay that allows viral evolution and replication to be studied inside single cells.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 24, 2020.